Shares of Ligand Pharmaceuticals (LGND +13.9%) are soaring since being removed from a a trading...

|About: Ligand Pharmaceuticals Inco... (LGND)|By:, SA News Editor

Shares of Ligand Pharmaceuticals (LGND +13.9%) are soaring since being removed from a a trading halt earlier this morning. The stock was halted after its partner GlaxoSmithKline (GSK +1%) announced the FDA has approved Promacta for the treatment of thrombocytopenia - a condition in patients with chronic hepatitis C that causes low blood platelet counts - which will allow them to initiate and maintain interferon-based therapy.